Tests acetazolamide as an add-on for treatment resistant schizophrenia
Compares acetazolamide with placebo in adults with treatment resistant schizophrenia.
Plain-language title generated from the registry record
Registry title: Acetazolamide for Treatment Resistant Schizophrenia
Key facts
- Where
- Pittsburgh, United StatesSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT04887792, who can take part
Where in United States
- University of PittsburghPittsburgh, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vishwajit Nimgaonkar, MD PhD
- Trial code
- NCT04887792
- Record updated
- 7 July 2026
- Original description
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.Read full original descriptionShow less
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Inclusion: Written informed consent; Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose); PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions; Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study; Not participating in another randomized controlled clinical trial (RCT).
Exclusion: Current or prior treatment with ACZ or history of hypersensitivity to ACZ; History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy; Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma; Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal; Pregnancy; Intellectual disability as defined in DSM 5.